Solid Biosciences Inc. SLDB External General And Administrative Expense — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Solid Biosciences Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s external general and administrative expense — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s external general and administrative expense — research and development expense?
- Solid Biosciences Inc. (SLDB) reported external general and administrative expense — research and development expense of $4.87M in Q4 2025.
- How has Solid Biosciences Inc.'s external general and administrative expense — research and development expense changed year-over-year?
- Solid Biosciences Inc.'s external general and administrative expense — research and development expense decreased by 3.2% year-over-year, from $5.03M to $4.87M.
- What is the long-term trend for Solid Biosciences Inc.'s external general and administrative expense — research and development expense?
- Over 2 years (2023 to 2025), Solid Biosciences Inc.'s external general and administrative expense — research and development expense has grown at a -0.4% compound annual growth rate (CAGR), from $19.64M to $19.47M.
- What does external general and administrative expense — research and development expense mean?
- This metric measures the research and development expenditures specifically allocated to a distinct business segment or product pipeline. It reflects the investment intensity in innovation, clinical trials, and scientific advancement for that particular area of the company's portfolio. Tracking this allows stakeholders to evaluate the capital allocation strategy and the commitment to long-term growth within specific therapeutic or product categories.